Post-Stroke Depression or Apathy? Differentiating and Treating
A 68-year-old right-handed man is 3 months post-left middle cerebral artery ischemic stroke. He has mild nonfluent aphasia (can follow simple commands, names 8/20 objects) and right hemiparesis. He now lives with his daughter. Over the past 6 weeks, his daughter reports he has stopped initiating conversation, sits in front of the TV for hours, and eats only when prompted. He does not cry or say he feels sad. On the PHQ-9 (administered with simplified yes/no due to aphasia), he scores 12, with points from anhedonia (2), fatigue (2), psychomotor retardation (2), and appetite (2), but 0 on depressed mood and 0 on worthlessness/guilt. He denies suicidal ideation. Neurological exam shows no new focal deficits; MRI shows an old left MCA infarct and moderate periventricular white matter disease. He is on aspirin and a statin. His daughter asks if he needs an antidepressant.
1. How would you differentiate post-stroke depression (PSD) from apathy or other post-stroke behavioral changes in this patient, and what would you do next diagnostically?
Read the worked answer
The key is that this patient's presentation is dominated by reduced initiation and goal-directed behavior without subjective sadness, guilt, or anhedonia reported by the patient himself. His PHQ-9 score is inflated by somatic and motor items that overlap with stroke sequelae (fatigue, psychomotor retardation, appetite) and by informant-reported anhedonia. Apathy after stroke is common, especially with frontal-subcortical involvement, and is characterized by diminished motivation, reduced goal-directed activity, and emotional blunting, but not necessarily dysphoria. PSD, by contrast, typically includes depressed mood or anhedonia plus other psychological symptoms (guilt, worthlessness, hopelessness). However, aphasia complicates assessment: he may not be able to express sadness. Use a structured informant interview (e.g., Stroke Aphasic Depression Questionnaire) and observe behavior. Also screen for medical contributors: hypothyroidism, B12 deficiency, medication side effects (e.g., beta-blockers, steroids), and pain. The periventricular white matter disease may contribute to apathy. Next steps: obtain collateral from daughter using a validated apathy scale (e.g., Apathy Evaluation Scale) and a depression informant measure; review medications; check TSH, B12, and basic labs; consider a trial of a selective serotonin reuptake inhibitor (SSRI) if depression is suspected, but recognize that apathy may not respond to antidepressants. Nonpharmacologic activation and behavioral strategies are first-line for apathy. Monitor response with both depression and apathy measures.
2. If you decide to start an antidepressant, which agent would you choose and why? What factors would guide dosing and monitoring in this patient with aphasia and stroke?
Read the worked answer
SSRIs are first-line for PSD due to better tolerability and fewer anticholinergic and cardiac effects than tricyclics. Sertraline and escitalopram have the most evidence in stroke. Avoid paroxetine due to anticholinergic burden and CYP2D6 inhibition. Start low (e.g., sertraline 25 mg daily) and titrate slowly because of age, stroke, and potential drug interactions (aspirin, statin). Monitor for hyponatremia (especially with diuretics), bleeding risk with aspirin (SSRIs increase bleeding risk), QT prolongation (escitalopram), and serotonin syndrome. Because of aphasia, use informant-rated scales and behavioral observation rather than self-report alone. Also assess for dysphagia before giving pills. Reassess in 2-4 weeks for side effects and at 6-8 weeks for efficacy. If no response, consider switching or augmenting, but first ensure apathy is not the primary problem. Nonpharmacologic interventions (behavioral activation, speech therapy, social engagement) should be concurrent.